In contrast to the DCs treated with control tumor lysate, which increased the proportion of conventional FoxP3+ CD4 Tregs, the PAM-treated tumor lysate did not potentiate the Treg-inducing capacity of DCs. The gene discussed is FOXP3; the disease is neoplasm.